IP Library Granted Patent US 9,296,791
Granted Patent B2
US 9,296,791 · App. 13/740,793 · Granted Mar 29, 2016

Mutant protein

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,296,791
App. No.
13/740,793
Granted
Mar 29, 2016
Kind
B2
Abstract

The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.

Claims (13)

1. In a method of separating one or more antibodies from a liquid, which method comprises:

(a) contacting said liquid with a separation matrix comprising ligands immobilised to a support;

(b) allowing antibodies to adsorb to said matrix by interaction with said ligands;

(c) optionally washing the adsorbed antibodies; and

(d) recovering antibodies by contacting said matrix with an eluent which releases the antibodies;

the improvement being that said ligands comprise one or more alkali-stable domain B of staphylococcal Protein A (SpA) wherein at least one glycine has been replaced by an alanine and at least the asparagine in position 23 has been replaced with a threonine.

2. The method of claim 1 , wherein the recovery of antibodies is achieved by adding an eluent having a pH in the range of 3.8-3.9.

3. The method of claim 1 , wherein at least 80% of the antibodies are recovered using an eluent having a pH in the range of 3.7-3.9.

4. The method of claim 1 , wherein at least 90% of the antibodies are recovered using an eluent having a pH in the range of 3.7-3.9.

5. The method of claim 1 , wherein at least 95% of the antibodies are recovered using an eluent having a pH in the range of 3.7-3.9.

6. The method of claim 1 , wherein the amino acid residues in position 21 and 52 are both asparagines.

7. The method of claim 3 , wherein the amino acid residues in position 21 and 52 are both asparagines.

8. The method of claim 1 , wherein the glycine at position 29 has been replaced with an alanine.

Assignments (3)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054299/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2016
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 038811/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2013
From: HOBER, SOPHIA; JOHANSSON, HANS J.
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 030124/0472 →